loading
전일 마감가:
$3.08
열려 있는:
$3.14
하루 거래량:
1.91M
Relative Volume:
1.59
시가총액:
$186.32M
수익:
-
순이익/손실:
$-36.95M
주가수익비율:
-3.6071
EPS:
-0.84
순현금흐름:
$-33.46M
1주 성능:
+16.99%
1개월 성능:
+65.57%
6개월 성능:
-23.48%
1년 성능:
-58.78%
1일 변동 폭
Value
$2.925
$3.14
1주일 범위
Value
$2.22
$3.33
52주 변동 폭
Value
$1.61
$11.20

Larimar Therapeutics Inc Stock (LRMR) Company Profile

Name
명칭
Larimar Therapeutics Inc
Name
전화
844-511-9056
Name
주소
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Name
직원
65
Name
트위터
Name
다음 수익 날짜
2025-03-24
Name
최신 SEC 제출 서류
Name
LRMR's Discussions on Twitter

LRMR을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
LRMR
Larimar Therapeutics Inc
3.03 186.32M 0 -36.95M -33.46M -0.84
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
441.30 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.83 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.14 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
241.20 28.51B 3.81B -644.79M -669.77M -6.24

Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-01-29 개시 Truist Buy
2024-10-16 개시 Oppenheimer Outperform
2024-10-03 개시 Wedbush Outperform
2024-10-02 개시 H.C. Wainwright Buy
2024-09-04 개시 Robert W. Baird Outperform
2024-04-03 개시 Leerink Partners Outperform
2023-11-17 업그레이드 Citigroup Neutral → Buy
2022-10-19 개시 Guggenheim Buy
2022-02-15 다운그레이드 William Blair Outperform → Mkt Perform
2021-02-10 개시 JMP Securities Mkt Outperform
2021-02-01 개시 William Blair Outperform
모두보기

Larimar Therapeutics Inc 주식(LRMR)의 최신 뉴스

pulisher
Jun 17, 2025

Millennium Management LLC Acquires Additional Shares in Larimar Therapeutics Inc - GuruFocus

Jun 17, 2025
pulisher
Jun 10, 2025

Larimar Therapeutics Reports Q1 2025 Results and Advances Nomlabofusp Development - MSN

Jun 10, 2025
pulisher
Jun 10, 2025

Head-To-Head Survey: Larimar Therapeutics (NASDAQ:LRMR) vs. Madrigal Pharmaceuticals (NASDAQ:MDGL) - Defense World

Jun 10, 2025
pulisher
Jun 04, 2025

ProShare Advisors LLC Makes New $71,000 Investment in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World

Jun 04, 2025
pulisher
May 28, 2025

Northern Trust Corp Acquires 14,185 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World

May 28, 2025
pulisher
May 23, 2025

Larimar Therapeutics, Inc.’s (LRMR): Analysts See 957% Upside Potential - MSN

May 23, 2025
pulisher
May 23, 2025

Larimar Therapeutics’ SWOT analysis: nomlabofusp’s potential lifts FA stock By Investing.com - Investing.com South Africa

May 23, 2025
pulisher
May 22, 2025

Larimar Therapeutics’ SWOT analysis: nomlabofusp’s potential lifts FA stock - Investing.com

May 22, 2025
pulisher
May 18, 2025

Traws Pharma Highlights Q1 2025 Financial Progress and Antiviral Developments - MyChesCo

May 18, 2025
pulisher
May 13, 2025

Larimar Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks

May 13, 2025
pulisher
May 04, 2025

Larimar Therapeutics Advances Nomlabofusp Amid Financial Loss - TipRanks

May 04, 2025
pulisher
May 02, 2025

Larimar Therapeutics Inc (NASDAQ: LRMR): Can A Stock Be -26.10% Lower Year-To-Date And Still Be A Loser? - Marketing Sentinel

May 02, 2025
pulisher
May 02, 2025

The time has not yet come to remove your chips from the table: Larimar Therapeutics Inc (LRMR) - Sete News

May 02, 2025
pulisher
May 02, 2025

Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC), Humana (HUM) and Larimar Therapeutics (LRMR) - The Globe and Mail

May 02, 2025
pulisher
May 02, 2025

Stock Traders Buy High Volume of Call Options on Larimar Therapeutics (NASDAQ:LRMR) - Defense World

May 02, 2025
pulisher
May 01, 2025

LRMR: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com

May 01, 2025
pulisher
May 01, 2025

Larimar Therapeutics Inc (LRMR)’s highs and lows: A closer look at its stock price fluctuations - uspostnews.com

May 01, 2025
pulisher
Apr 30, 2025

Larimar: Q1 Earnings Snapshot - MySA

Apr 30, 2025
pulisher
Apr 30, 2025

Larimar Therapeutics, Inc. SEC 10-Q Report - TradingView

Apr 30, 2025
pulisher
Apr 30, 2025

Investor’s Delight: Larimar Therapeutics Inc (LRMR) Closes Strong at 2.39, Up 1.70 - DWinneX

Apr 30, 2025
pulisher
Apr 30, 2025

Larimar (LRMR) Advances Clinical Program Towards Potential FDA A - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Investing in Larimar Therapeutics Inc (LRMR) Is Getting More Attractive - knoxdaily.com

Apr 30, 2025
pulisher
Apr 30, 2025

Larimar (LRMR) Advances Clinical Program Towards Potential FDA Approval | LRMR Stock News - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Larimar Therapeutics Reports First Quarter 2025 Financial Results - GlobeNewswire

Apr 30, 2025
pulisher
Apr 30, 2025

Larimar's Friedreich's Ataxia Drug Gets FDA Accelerated Approval Path While Cash Reserves Surge - Stock Titan

Apr 30, 2025
pulisher
Apr 27, 2025

Larimar Therapeutics awards key executives performance-based stock - MSN

Apr 27, 2025
pulisher
Apr 23, 2025

Market Watch Highlights: Larimar Therapeutics Inc (LRMR) Ends on an Upturn Note at 2.38 - DWinneX

Apr 23, 2025
pulisher
Apr 23, 2025

Larimar Therapeutics Inc (LRMR) Stock: A Comprehensive 52-Week Review - investchronicle.com

Apr 23, 2025
pulisher
Apr 23, 2025

Nothing is Better Than Larimar Therapeutics Inc (LRMR) stock at the moment - Sete News

Apr 23, 2025
pulisher
Apr 22, 2025

The Potential Rise in the Price of Larimar Therapeutics Inc (LRMR) following insiders activity - knoxdaily.com

Apr 22, 2025
pulisher
Apr 22, 2025

Larimar Therapeutics Inc (LRMR)’s results reveal risk - uspostnews.com

Apr 22, 2025
pulisher
Apr 04, 2025

Larimar Therapeutics: Initiating Hold Rating With Upcoming Catalysts - Seeking Alpha

Apr 04, 2025
pulisher
Apr 03, 2025

An In-Depth Look at Larimar Therapeutics Inc Inc. (LRMR) Price Performance During Market Crashes - investchronicle.com

Apr 03, 2025
pulisher
Apr 01, 2025

Larimar to seek accelerated approval of FA therapy nomlabofusp this year - Friedreich's Ataxia News

Apr 01, 2025
pulisher
Mar 31, 2025

Q1 EPS Estimate for Larimar Therapeutics Lowered by Analyst - MarketBeat

Mar 31, 2025
pulisher
Mar 28, 2025

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth? - Yahoo Finance

Mar 28, 2025
pulisher
Mar 28, 2025

Larimar Therapeutics Advances Nomlabofusp Program Amid Regulatory Support - MSN

Mar 28, 2025
pulisher
Mar 26, 2025

Larimar Therapeutics (NASDAQ:LRMR) Given Buy Rating at Guggenheim - Defense World

Mar 26, 2025
pulisher
Mar 26, 2025

HC Wainwright Issues Positive Forecast for Larimar Therapeutics (NASDAQ:LRMR) Stock Price - Defense World

Mar 26, 2025
pulisher
Mar 26, 2025

LRMR stock touches 52-week low at $2.21 amid market challenges - Investing.com

Mar 26, 2025
pulisher
Mar 26, 2025

Larimar Therapeutics (NASDAQ:LRMR) Price Target Cut to $10.00 by Analysts at Robert W. Baird - Defense World

Mar 26, 2025
pulisher
Mar 25, 2025

Jones Trading maintains $14 target on Larimar Therapeutics stock By Investing.com - Investing.com UK

Mar 25, 2025
pulisher
Mar 25, 2025

Larimar Therapeutics Reports 2024 Financial Results and Development Progress - TipRanks

Mar 25, 2025
pulisher
Mar 24, 2025

FDA open to new surrogate endpoint for FA drug approval By Investing.com - Investing.com Australia

Mar 24, 2025
pulisher
Mar 24, 2025

Larimar: Q4 Earnings Snapshot - mySA

Mar 24, 2025
pulisher
Mar 24, 2025

Wedbush Cuts Price Target on Larimar Therapeutics to $17 From $22, Maintains Outperform Rating - MarketScreener

Mar 24, 2025
pulisher
Mar 24, 2025

FDA open to new surrogate endpoint for FA drug approval - Investing.com India

Mar 24, 2025
pulisher
Mar 24, 2025

Larimar: Q4 Earnings Snapshot -March 24, 2025 at 07:17 am EDT - MarketScreener

Mar 24, 2025

Larimar Therapeutics Inc (LRMR) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.50
price down icon 1.11%
$35.87
price up icon 1.70%
$20.60
price down icon 3.38%
$99.49
price down icon 2.21%
$106.72
price up icon 0.55%
biotechnology ONC
$241.20
price down icon 5.22%
자본화:     |  볼륨(24시간):